Do analysts prefer XLO or YDES?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, XLO or YDES?

YD Bio has lower revenue, but higher earnings than Xilio Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xilio Therapeutics $43.77M 1.38 -$35.04M -$1.64 N/A YD Bio N/A N/A N/A N/A N/A

Does the media prefer TARA or XLO?

In the previous week, Xilio Therapeutics had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 2 mentions for Xilio Therapeutics and 1 mentions for Protara Therapeutics. Xilio Therapeutics' average media sentiment score of 1.47 beat Protara Therapeutics' score of 0.25 indicating that Xilio Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Xilio Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ARCT or XLO?

Arcturus Therapeutics presently has a consensus price target of $20.00, suggesting a potential upside of 39.47%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcturus Therapeutics is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.60 Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer ARCT or XLO?

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Arcturus Therapeutics and 2 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.47 beat Arcturus Therapeutics' score of 0.97 indicating that Xilio Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xilio Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GALT or XLO?

Galectin Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 183.51%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer GALT or XLO?

In the previous week, Galectin Therapeutics had 4 more articles in the media than Xilio Therapeutics. MarketBeat recorded 6 mentions for Galectin Therapeutics and 2 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.47 beat Galectin Therapeutics' score of 1.05 indicating that Xilio Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xilio Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate XLO or EBS?

Emergent Biosolutions has a consensus price target of $10.00, suggesting a potential upside of 93.12%. Given Emergent Biosolutions' stronger consensus rating and higher possible upside, analysts plainly believe Emergent Biosolutions is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Emergent Biosolutions 2 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.17

Does the media refer more to XLO or EBS?

In the previous week, Emergent Biosolutions had 2 more articles in the media than Xilio Therapeutics. MarketBeat recorded 4 mentions for Emergent Biosolutions and 2 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.47 beat Emergent Biosolutions' score of -0.04 indicating that Xilio Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xilio Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Emergent Biosolutions 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Xilio Therapeutics (XLO) Competitors

$9.19 -0.04 (-0.43%)

Closing price 04:00 PM Eastern

Extended Trading

$9.20 +0.02 (+0.16%)

As of 04:10 PM Eastern

Compare

XLO vs. YDES, TARA, ARCT, GALT, and EBS

Should you buy Xilio Therapeutics stock or one of its competitors? Xilio Therapeutics's main competitors and comparable companies include YD Bio (YDES), Protara Therapeutics (TARA), Arcturus Therapeutics (ARCT), Galectin Therapeutics (GALT), and Emergent Biosolutions (EBS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Xilio Therapeutics compare to YD Bio?

Xilio Therapeutics (NASDAQ:XLO) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

YD Bio has lower revenue, but higher earnings than Xilio Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.38	-$35.04M	-$1.64	N/A
YD Bio	N/A	N/A	N/A	N/A	N/A

54.3% of Xilio Therapeutics shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Xilio Therapeutics had 2 more articles in the media than YD Bio. MarketBeat recorded 2 mentions for Xilio Therapeutics and 0 mentions for YD Bio. Xilio Therapeutics' average media sentiment score of 1.47 beat YD Bio's score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Xilio Therapeutics	Positive
YD Bio	Neutral

YD Bio has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. YD Bio's return on equity of 0.00% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-34.06%	-71.99%	-20.43%
YD Bio	N/A	N/A	N/A

Summary

Xilio Therapeutics beats YD Bio on 5 of the 8 factors compared between the two stocks.

How does Xilio Therapeutics compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Protara Therapeutics presently has a consensus target price of $26.25, suggesting a potential upside of 578.29%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Protara Therapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Xilio Therapeutics had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 2 mentions for Xilio Therapeutics and 1 mentions for Protara Therapeutics. Xilio Therapeutics' average media sentiment score of 1.47 beat Protara Therapeutics' score of 0.25 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Xilio Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protara Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Protara Therapeutics' return on equity of -41.72% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-41.72%	-38.78%
Xilio Therapeutics	-34.06%	-71.99%	-20.43%

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Protara Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, suggesting that its stock price is 114% less volatile than the broader market.

Xilio Therapeutics has higher revenue and earnings than Protara Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A
Xilio Therapeutics	$43.77M	1.38	-$35.04M	-$1.64	N/A

Summary

Protara Therapeutics beats Xilio Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Xilio Therapeutics compare to Arcturus Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Arcturus Therapeutics presently has a consensus price target of $20.00, suggesting a potential upside of 39.47%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcturus Therapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Arcturus Therapeutics and 2 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.47 beat Arcturus Therapeutics' score of 0.97 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xilio Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xilio Therapeutics has a net margin of -34.06% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%
Xilio Therapeutics	-34.06%	-71.99%	-20.43%

Arcturus Therapeutics has a beta of 2.39, indicating that its stock price is 139% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market.

94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Xilio Therapeutics has lower revenue, but higher earnings than Arcturus Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	4.97	-$65.78M	-$3.31	N/A
Xilio Therapeutics	$43.77M	1.38	-$35.04M	-$1.64	N/A

Summary

Arcturus Therapeutics beats Xilio Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Xilio Therapeutics compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

In the previous week, Galectin Therapeutics had 4 more articles in the media than Xilio Therapeutics. MarketBeat recorded 6 mentions for Galectin Therapeutics and 2 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.47 beat Galectin Therapeutics' score of 1.05 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xilio Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Galectin Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Galectin Therapeutics' return on equity of 0.00% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Xilio Therapeutics	-34.06%	-71.99%	-20.43%

Galectin Therapeutics has higher earnings, but lower revenue than Xilio Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Xilio Therapeutics	$43.77M	1.38	-$35.04M	-$1.64	N/A

Galectin Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 183.51%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Galectin Therapeutics has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, suggesting that its share price is 114% less volatile than the broader market.

Summary

Galectin Therapeutics beats Xilio Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Xilio Therapeutics compare to Emergent Biosolutions?

Xilio Therapeutics (NASDAQ:XLO) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Emergent Biosolutions has higher revenue and earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.38	-$35.04M	-$1.64	N/A
Emergent Biosolutions	$742.90M	0.36	$52.60M	-$3.55	N/A

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Emergent Biosolutions had 2 more articles in the media than Xilio Therapeutics. MarketBeat recorded 4 mentions for Emergent Biosolutions and 2 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.47 beat Emergent Biosolutions' score of -0.04 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Emergent Biosolutions	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Emergent Biosolutions has a consensus price target of $10.00, suggesting a potential upside of 93.12%. Given Emergent Biosolutions' stronger consensus rating and higher possible upside, analysts plainly believe Emergent Biosolutions is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Xilio Therapeutics has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market.

Emergent Biosolutions has a net margin of -22.95% compared to Xilio Therapeutics' net margin of -34.06%. Emergent Biosolutions' return on equity of 16.35% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-34.06%	-71.99%	-20.43%
Emergent Biosolutions	-22.95%	16.35%	6.17%

Summary

Emergent Biosolutions beats Xilio Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Xilio Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XLO vs. The Competition

Export

Metric	Xilio Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$60.47M	$3.99B	$7.30B	$12.71B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-5.60	11.76	271.39	24.11
Price / Sales	1.38	1,296.80	604.56	77.78
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	1.26	17.27	11.18	6.40
Net Income	-$35.04M	-$22.72M	$3.46B	$348.28M
7 Day Performance	-3.16%	2.83%	1.97%	0.95%
1 Month Performance	6.24%	9.67%	7.30%	5.15%
1 Year Performance	-6.64%	54.74%	24.74%	16.18%

Xilio Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XLO Xilio Therapeutics	0.2061 of 5 stars	$9.19 -0.4%	N/A	-6.2%	$60.47M	$43.77M	N/A	70
YDES YD Bio	N/A	$3.98 +18.1%	N/A	N/A	$238.56M	$596.82K	N/A	N/A	High Trading Volume
TARA Protara Therapeutics	1.6371 of 5 stars	$3.98 flat	$26.25 +559.5%	+23.8%	$234.61M	N/A	N/A	30
ARCT Arcturus Therapeutics	1.8962 of 5 stars	$8.21 +0.9%	$24.25 +195.4%	-27.3%	$231.36M	$18.72M	N/A	180
GALT Galectin Therapeutics	2.2055 of 5 stars	$3.52 +0.3%	$11.00 +212.5%	-10.2%	$231.16M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XLO) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xilio Therapeutics (XLO) Competitors

XLO vs. YDES, TARA, ARCT, GALT, and EBS

How does Xilio Therapeutics compare to YD Bio?

Summary

How does Xilio Therapeutics compare to Protara Therapeutics?

Summary

How does Xilio Therapeutics compare to Arcturus Therapeutics?

Summary

How does Xilio Therapeutics compare to Galectin Therapeutics?

Summary

How does Xilio Therapeutics compare to Emergent Biosolutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xilio Therapeutics (XLO) Competitors

XLO vs. YDES, TARA, ARCT, GALT, and EBS

How does Xilio Therapeutics compare to YD Bio?

Do analysts prefer XLO or YDES?

Which has preferable earnings and valuation, XLO or YDES?

Do insiders & institutionals hold more shares of XLO or YDES?

Does the media favor XLO or YDES?

Is XLO or YDES more profitable?

Summary

How does Xilio Therapeutics compare to Protara Therapeutics?

Do analysts rate TARA or XLO?

Does the media prefer TARA or XLO?

Is TARA or XLO more profitable?

Do insiders and institutionals hold more shares of TARA or XLO?

Which has more risk & volatility, TARA or XLO?

Which has stronger valuation and earnings, TARA or XLO?

Summary

How does Xilio Therapeutics compare to Arcturus Therapeutics?

Do analysts recommend ARCT or XLO?

Does the media prefer ARCT or XLO?

Is ARCT or XLO more profitable?

Which has more volatility and risk, ARCT or XLO?

Do institutionals & insiders hold more shares of ARCT or XLO?

Which has higher valuation and earnings, ARCT or XLO?

Summary

How does Xilio Therapeutics compare to Galectin Therapeutics?

Does the media prefer GALT or XLO?

Is GALT or XLO more profitable?

Which has preferable earnings & valuation, GALT or XLO?

Do analysts rate GALT or XLO?

Do insiders and institutionals believe in GALT or XLO?

Which has more volatility and risk, GALT or XLO?

Summary

How does Xilio Therapeutics compare to Emergent Biosolutions?

Which has better earnings and valuation, XLO or EBS?

Do institutionals & insiders have more ownership in XLO or EBS?

Does the media refer more to XLO or EBS?

Do analysts rate XLO or EBS?

Which has more risk & volatility, XLO or EBS?

Is XLO or EBS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools